Table 1 Baseline characteristics of the study population by treatment group and gender
Characteristic | Placebo (n = 79) | ch-OSA (n = 87) | Male (n = 46) | Female (n = 120) |
|---|---|---|---|---|
Age (years) | 62.2 ± 7.7 | 61.7 ± 6.5 | 61.0 ± 7.2 | 62.3 ± 7.0 |
Women | 55 (69.6) | 65 (74.7) | 0 | 120 (100) |
Body mass index (kg/m2) | 29.5 ± 5.2 | 29.5 ± 5.4 | 29.1 ± 4.7 | 29.6 ± 5.6 |
Menopausal Status | 1 pre (1.5) | 1 pre (1.8) | - | 2 pre (1.7) |
0 peri (1.5) | 1 peri | 1 peri (0.8) | ||
54 post (98.2) | 63 post (96.9) | 117 post (97.5) | ||
Kellgren and Lawrence grade II | 48 (60.8) | 59 (67.8) | 26 (56.5) | 81 (67.5) |
Kellgren and Lawrence grade III | 31 (39.2) | 28 (32.2) | 20 (43.5) | 39 (32.5) |
Likert pain score 2 | 38 (48.1) | 32 (36.8) | 19 (41.3) | 51 (42.5) |
Likert pain score 3 | 41 (51.9) | 55 (63.2) | 27 (58.7) | 69 (57.5) |
WOMAC Total (/100 mm) | 43.1 ± 20.3 | 40.9 ± 19.4 | 42.2 ± 21.5 | 41.9 ± 19.2 |
WOMAC Pain (/100 mm) | 41.2 ± 20.3 | 38.2 ± 19.8 | 41.9 ± 20.9 | 38.7 ± 19.7 |
WOMAC Stiffness (/100 mm) | 45.3 ± 24.6 | 44.0 ± 23.5 | 44.9 ± 23.4 | 44.5 ± 24.3 |
WOMAC Function (/100 mm) | 43.4 ± 21.2 | 41.4 ± 19.8 | 42.0 ± 22.5 | 42.5 ± 19.7 |
Subject Global Assessment (/100 mm) | 49.4 ± 21.8 | 50.1 ± 18.2 | 51.3 ± 22.4 | 49.2 ± 19.0 |
CTX-II/Creatinine (ng/mmol) | 413.1 ± 189.6 | 430.4 ± 212.7 | 378.5 ± 162.8 | 441.0 ± 213.9 |
COMP (U/L) | 10.8 ± 2.8 | 10.7 ± 2.8 | 11.0 ± 2.8 | 10.6 ± 2.8 |
Estradiol (ng/L) | - | - | 35.5 ± 31.0 | 22.0 ± 36.2 a |